DIGITALDX
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Vivian Lu
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Gisela Paulsen
      • Michael Doherty
      • Laura Yecies
      • Laura Mezey
      • Ramin Khaksar
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Maciera-Kaufman
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
    • Press Releases
    • Events/Video
PORTFOLIO COMPANY NEWS
(Click on title to see full article)
Picture
August 30, 2022 — Optina Diagnostics Earns Frost & Sullivan’s 2022 North American Technology Innovation Leadership Award
January 24, 2022 — Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation (ADDF)
October 28, 2021 — Optina Diagnostics closes an oversubscribed Series-A Round of CA$24.8 million, with an additional $2.1m Note on the heels of this from the Alzheimer’s Dementia Discovery Fund
April 1, 2021 — How the brain-eye connection aims to make memory loss a souvenir
July 29, 2020 — Optina Diagnostics announces a collaborative clinical research study with the Alzheimer Center Amsterdam, Amsterdam UMC
May 13, 2020 — Optina Diagnostics receives 510(k) clearance from U.S. FDA for its MHRC-C1, permitting hyperspectral imaging of the retina
November 6, 2019 — Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics
June 14, 2019 — Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease
October 10, 2018 — Zoic Capital, Desjardins Capital and Other Investors Join Montréal-based Alzheimer Early Detection Optina Diagnostics $4 M Seed Round
August 7,  2018 — Optina Diagnostics Looks to Advance Biomarker Discovery Through Collaboration with Imagia
April 13,  2017 — New technologies feed optimism within Alzheimer research SEARCH
Picture
March 22, 2022 — NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients
​
March 4, 2022 — NephroSant promotes QSant kidney study
March 3, 2022 — NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Kidney-Transplant Rejection Events
September 22, 2021 — NephroSant Secures Medicare Coverage for QSant, the First Urine-based Kidney Transplant Rejection Test, and Plans 2022 Launch
March 19, 2021 — NephroSant Readies Launch of Kidney Transplant Rejection Assay
March 16, 2021 — NephroSant Announces $16 Million Series A, Led by DaVita Venture Group
Picture
March 31, 2021 — Women's Health Tech Wednesdays | Digital DX Ventures and Trayt
January 19, 2020 — Founder Series with Malekeh Amini, CEO of Trayt: Challenges of running a mental health startup
March 28, 2019 — InnovatorMD
April 20, 2018 — Trayt debuts mobile app to track and help treat autism, ADHD
August 23, 2018 — Tech exec works to help treat kids' brain disorders
Picture
August 23, 2022 — Biotia has raised an oversubscribed $8 million Series A round led by OCA Ventures.
August 15, 2022 — Biotia Selected By Mayo Clinic Platform To Accelerate The Success of Its AI Diagnostic Software

August 2, 2022 — Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2
April 9, 2021 — A National Open Genomics Consortium for the COVID-19 Response
November 19, 2020 — Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
June 15, 2020 — Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and Rare Disease Product Lifecycle
September 22, 2017 — Metagenomic characterization of ambulances across the USA
Picture
July 1, 2022 — Danish Startup GLX Analytix Prepares for Commercialization With Seed Investment
June 14, 2022 — GLX Analytix Receives Funds from DigitalDx Ventures, Vaekstfonden & CBC Investment Group to Accelerate Growth
2019 — GLX Analytix has been voted Roche Startup of the Year 2019
Picture
May 24, 2022  — Silicon Valley based Diagnostics Company AEENA Dx Welcomes new Board Member
October 29, 2020  — Aeena Dx Welcomes Robert Weigle as CEO
Picture
August 16, 2022 — Inc. -- Inc. 5,000 Names Maryland's Fastest Growing Companies in 2022
July 30, 2022 — BioBuzz Show
-- Gaithersburg’s 20/20 GeneSystems Honored As It Opens ‘First-of-its-Kind’ Diagnostics Incubator in Montgomery County
September 29, 2021 — LabPulse.com -- 20/20 GeneSystems Launches Clinical Lab Innovation Facility
September 29, 2021 — CLP magazine
-- 20/20 GeneSystems Launches Clinical Lab Innovation Facility
August 17, 2021 — Inc.
-- 20/20 GeneSystems, Inc. Ranks No. 770 on the 2021 Inc. 5000, With Three-Year Revenue Growth of 640 Percent
August 13, 2020 — NBC4
-- Maryland Legislators Urge More Aggressive Use of Antibody Tests as Local Company Aims to Advance Research
April 10, 2020 — ABC7
-- Can antibody blood tests confirm you're immune, get you out of quarantine?
October 15, 2020 — 20/20 GeneSystems Launching First COVID-19 Rapid Antibody Test Authorized by FDA for Point-of-Care Use
March 27, 2020 — Baltimore Business Journal -- These Md. companies are racing to create coronavirus testing supplies
Picture
July 25, 2022 Delphi Diagnostics SET2,3 Test Clarifies Therapy Options for Certain Breast Cancer Patients
June 13, 2022 — Delphi Diagnostics: SET2,3TM Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
February 15
-- Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial
December 15, 2021
-- SET2,3™ index adds independent, complementary information to personalize breast cancer treatment
Disclaimer
Terms & Conditions
Privacy Policy
Investment Inquiries
Contact
Picture
Picture
Picture
 Copyright © 2022 All Rights Reserved
  • People
    • TEAM >
      • Michele Colucci
      • Eric Weiss
      • Anula Jayasuriya
      • Vanessa Small
      • David Kirk
      • Melody Po
      • Sharad Mishra
      • Maureen Downey
      • Valerie Kozak
      • Vivian Lu
    • EIR >
      • Jerry Lanchbury
      • Debbie Lin
      • Gisela Paulsen
      • Michael Doherty
      • Laura Yecies
      • Laura Mezey
      • Ramin Khaksar
      • Anita Samarth
      • L. Jasmine Kim
      • Swami Raote
    • Advisors >
      • Deborah DiSanzo
      • Russ Altman
      • Rebecca Maciera-Kaufman
      • Saul A. Fox
      • Girish Narayan
      • Maureen A. Spivack
      • Ferid Murad
      • Ronald Wyatt
    • Fellows >
      • Apply for Fellowship
  • Focus
    • About Us
    • Market Opportunity
    • Market Segmentation
  • Portfolio
    • Portfolio Companies
    • News
  • Impact
    • ESG + DEI
    • Gender Parity
  • Press
    • Press Releases
    • Events/Video